PharmaCyte Biotech, Inc.
PMCB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001157075
No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding PharmaCyte Biotech, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 25 | 25 | 0 |
| Shares | 576.8K | 433.4K | −143.4K (−24.9%) |
| Value | $632.1K | $419.9K | −$212.2K (−33.6%) |
New holders (6)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 14,531 | $14.1K | 0.00% |
| Simplex Trading, LLC | 1,100 | $1.00K | 0.00% |
| Financial Consulate, Inc | 2 | $2 | 0.00% |
| Citigroup Inc | 1 | $1 | 0.00% |
| BlackRock, Inc. | 1 | $1 | 0.00% |
| Accredited Wealth Management, LLC | 50 | $1 | 0.00% |
Sold out (6)
Institutions that held PharmaCyte Biotech, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Susquehanna International Group, LLP | 27,606 | $30.4K |
| Dimensional Fund Advisors LP | 20,299 | $22.3K |
| National Bank of Canada | 3,300 | $3.56K |
| Raymond James Financial Inc | 44 | $48 |
| Park Square Financial Group, LLC | 37 | $40 |
| Koesten, Hirschmann & Crabtree, INC. | 1 | $2 |